CoChat

Enhanced neoepitope-specific immunity following neoadjuvant PD-L1 and TGF-β blockade in HPV-unrelated head and neck cancer

Open access
Redman, Jason M., Friedman, Jay, Robbins, Yvette, Sievers, Cem, Yang, Xinping, Lassoued, Wiem, Sinkoe, Andrew, Papanicolau-Sengos, Antonios, Lee, Chyi-Chia, Marte, Jennifer L., Turkbey, Evrim, Mydlarz, Wojtek, Joshi, Arjun, London, Nyall R., Pierce, Matthew, Taylor, Rodney, Hong, Steven, Nguyen, Andy, Soon-Shiong, Patrick, Schlom, Jeffrey, Gulley, James L., Allen, Clint T. · 2022 · Journal of Clinical Investigation
Cited by 74

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

BACKGROUNDHead and neck squamous cell carcinoma not associated with HPV (HPV-unrelated HNSCC) is associated with a high rate of recurrence and poor survival.METHODSWe conducted a clinical trial in 14 patients with newly diagnosed HPV-unrelated HNSCC to evaluate the safety and efficacy of neoadjuvant bintrafusp alfa, a bifunctional fusion protein that blocks programmed death ligand 1 (PD-L1) and neutralizes TGF-β.RESULTSBintrafusp alfa was well tolerated, and no treatment-associated surgical delays or complications occurred. Objective pathologic responses (PRs) were observed, and 12 of the 14 (86%) patients were alive and disease free at 1 year. Alterations in Treg infiltration and spatial distribution relative to proliferating CD8+ T cells indicated a reversal of Treg immunosuppression in the primary tumor. Detection of neoepitope-specific tumor T cell responses, but not virus-specific responses, correlated with the development of a PR. Detection of neoepitope-specific responses and PRs in tumors was not correlated with genomic features or tumor antigenicity but was associated with reduced pretreatment myeloid cell tumor infiltration. These results indicate that dual PD-L1 and TGF-β blockade can safely enhance tumor antigen-specific immunity and highlight the feasibility of multimechanism neoadjuvant immunotherapy for patients with HPV-unrelated HNSCC.CONCLUSIONOur studies provide insight into the ability of neoadjuvant immunotherapy to induce polyclonal neoadjuvant-specific T cell responses in tumors and suggest that features of the tumor microenvironment, such as myeloid cell infiltration, may be a major determinant of enhanced antitumor immunity following such treatment.TRIAL REGISTRATIONClinicalTrials.gov NCT04247282.FUNDINGThis work was funded by the Center for Cancer Research, the NCI, and the Intramural Research Program of the NIDCD, NIH. Bintrafusp alfa was provided by the health care business of Merck KGaA (Darmstadt, Germany), through a Cooperative Research and Development Agreement with the NCI. Additional funding was provided by ImmunityBio through a Cooperative Research and Development Agreement with the NIDCD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci161400

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Cited by

See all 74

Metadata

Authors
Redman, J. M., Friedman, J., Robbins, Y., Sievers, C., Yang, X., Lassoued, W., Sinkoe, A., Papanicolau-Sengos, A., Lee, C.-C., Marte, J. L., Turkbey, E., Mydlarz, W., Joshi, A., London, N. R., Pierce, M., Taylor, R., Hong, S., Nguyen, A., Soon-Shiong, P., Schlom, J., Gulley, J. L., & Allen, C. T.
Venue
Journal of Clinical Investigation
Published
2022-09-15
Volume
132
Issue
18
ISSN
  • 0021-9738 (ISSN-L)
  • 1558-8238
OpenAlex
W4283207450
Cited by
74
References
12
FWCI
5.71
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Enhanced neoepitope-specific immunity following neoadjuvant PD-L1 and TGF-β blockade in HPV-unrelated head and neck cancer. https://app.cochat.ai/papers/10.1172/jci161400
The paper
Redman, J. M., Friedman, J., Robbins, Y., Sievers, C., Yang, X., Lassoued, W., Sinkoe, A., Papanicolau-Sengos, A., Lee, C.-C., Marte, J. L., Turkbey, E., Mydlarz, W., Joshi, A., London, N. R., Pierce, M., Taylor, R., Hong, S., Nguyen, A., Soon-Shiong, P., . . . Allen, C. T. (2022). Enhanced neoepitope-specific immunity following neoadjuvant PD-L1 and TGF-β blockade in HPV-unrelated head and neck cancer. Journal of Clinical Investigation. https://doi.org/10.1172/jci161400

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.